Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer

Table 1 Association of macrophage migration inhibitory factor expression with clinicopathological features of gastric cancer n (%)

Variable	MIF
	All cases	Low expression	High expression	P value1
Age (yr)2				0.819
≤ 61	55	16 (29.09)	39 (70.91)
> 61	61	20 (32.79)	41 (67.21)
Sex				0.598
Male	74	21 (28.38)	53 (71.62)
Female	43	15 (34.88)	28 (65.12)
Tumor differentiation				0.049
Well	5	1 (20.00)	4 (80.00)
Moderate	34	16 (47.06)	18 (52.94)
Poor	78	19 (24.36)	59 (75.64)
Tumor stage				0.001
I and II	27	16 (59.26)	11 (40.74)
III	51	14 (27.45)	37 (72.55)
IV	39	6 (15.38)	33 (84.62)
T stage				0.034
T1 and T2	14	8 (57.14)	6 (42.86)
T3	75	23 (30.67)	52 (69.33)
T4	28	5 (17.86)	23 (82.14)
Lymph node metastasis				0.001
No (N0)	24	16 (66.67)	8 (33.33)
Yes (Nx)	93	20 (21.51)	73 (78.49)
Distant metastasis				0.564
M0	99	32 (32.32)	67 (67.68)
M1	18	4 (22.22)	14 (77.78)

¹χ² test;

²Median age.

Table 2 Cox’s multivariate analysis of prognostic factors for overall survival

Characteristic	Hazards ratio	95%CI	P value
Age ( ≤ 61 yr vs > 61 yr)	1.099	0.719-1.680	0.663
Sex (male vs female)	1.202	0.779-1.855	0.406
Tumor size ( ≤ 3 cm vs > 3 cm)	1.606	0.964-2.677	0.069
Stage (I-II vs III-V)	1.885	1.171-3.305	0.009
Differentiation (well to moderate vs poor)	1.258	0.777-2.039	0.351
MIF expression (low vs high)	1.784	1.338-2.380	< 0.001